Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Wugen Announces Dosing of First Patients in Pivotal Trial of Off-the-Shelf, Allogeneic, ...

Summary by Hastings Tribune
- Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic activity with an overall response rate of 91% and composite complete remission rate of 73% in heavily pretreated patients with R/R T-ALL/LBL

1 Articles

Hastings TribuneHastings Tribune
Center

Wugen Announces Dosing of First Patients in Pivotal Trial of Off-the-Shelf, Allogeneic, ...

- Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic activity with an overall response rate of 91% and composite complete remission rate of 73% in heavily pretreated patients with R/R T-ALL/LBL

·Nebraska, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Hastings Tribune broke the news in Nebraska, United States on Thursday, March 20, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Hastings, Nebraska icon

Hastings, Nebraska

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal